The Distribution Margin Turned, the Raise Was Operational, and the Multiple Already Paid for Both

Results vs. Consensus

Q2 FY2026 Scorecard

No published consensus exists for adjusted operating profit or for the individual segments under the structure McKesson reported on this quarter. The company announced a four-segment reorganization on September 18, three weeks before the print, and recast five prior quarters onto it. Sell-side models were being re-based in the interval, so any segment-level Street number for this quarter is unreliable and we do not claim a beat or miss against one.

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Every prior-period segment figure below is McKesson's own recast, published September 18 and reproduced in the Q2 release. The comparison is worth making because it is the only clean way to see whether the margin trend we flagged in August actually changed, and it did.

Adjusted EPS Bridge, Q2 FY25 to Q2 FY26

This is the single most useful artifact in the disclosure package, and it reads very differently from the bridge McKesson presented in August. Three months ago the tax rate cost $0.76 and the absence of prior-year investment gains cost another $0.61, so $1.37 of headwind consumed almost all of the $1.29 of operating contribution. This quarter every line except a small residual points the same direction.

Quality of Beat/Miss

• Revenue. Consolidated revenue of $103,150M missed a $104,150M consensus by roughly $1.0B. This is the least important line in the release. At the company's blended 1.58% adjusted operating margin, a $1.0B revenue shortfall is about $16M of operating profit, or roughly $0.10 per share after tax, against a beat of $0.82. Distributors are paid fees per unit rather than a spread on price, so revenue is a volume-and-mix readout, not an earnings driver. The 10-Q attributes the $6.5B of North American Pharmaceutical revenue growth almost entirely to sales to U.S. pharmacies and healthcare providers, up $6.4B on retail national account volume, "partially offset by branded to generic drug conversions." Generic conversion suppresses revenue dollars and lifts the fee margin, which is part of why the segment margin expanded on a light top line.
• Margins. Adjusted gross margin slipped 4 basis points to 3.43%, and adjusted operating margin expanded 20 basis points to 1.58%. The entire delta is operating expense. Adjusted operating expenses fell 1% in absolute dollars on 10% more revenue, taking the ratio of adjusted operating expense to adjusted gross profit from 61.3% to 55.6%, an improvement of 570 basis points against 450 basis points in the first quarter. That ratio is the cleanest single readout of the automation program, and it has now improved at an accelerating rate for two consecutive quarters.
• EPS. Adjusted EPS grew 39% and GAAP EPS grew 377%, the latter flattered by a prior-year quarter that carried a $643M charge on the Canadian retail disposal and a $227M business rationalization charge. The more useful comparison is the gap between the two: $0.94 of add-backs against $8.92 of GAAP EPS this quarter, versus $2.01 against $6.25 in the first quarter. The adjusted series is far closer to the reported economics than it was three months ago, which materially improves one of the three bear points we set at initiation.

Segment Performance

McKesson reported for the first time under a four-segment structure announced on September 18 and effective this quarter. The old U.S. Pharmaceutical segment has been split, with core distribution in the U.S. and Canada combined into North American Pharmaceutical and the specialty, provider-services, and practice-management assets pulled into a new Oncology & Multispecialty segment. The old International segment is gone, with Norway moved to Other. Prior periods are recast; consolidated results and EPS are unchanged.

North American Pharmaceutical: The Margin Finally Went the Right Way

Revenue grew 8% to $86,481M and adjusted operating profit grew 13% to $851M, at a 0.98% margin that is 4 basis points wider than a year ago. On the recast basis this segment ran a 0.91% margin in the June quarter against 1.03% a year earlier, a 12 basis point contraction. One quarter later it is expanding. That is the sequence that matters, and it is the first genuine evidence against the central bear point of our initiation.

It happened in a quarter when the dilutive input got larger, not smaller. GLP-1 revenue was $13.2B, up approximately $2.6B or 24% year over year and 6% sequentially, which is 15.3% of segment revenue and 12.8% of the consolidated top line. The segment absorbed a growing, fee-bearing, high-priced product line growing three times faster than the segment around it, and still widened its margin.

"Revenues from GLP-1 medications were $13.2 billion in the quarter, an increase of approximately $2.6 billion or 24% when compared to the prior year. On a sequential basis, GLP-1 revenue increased 6%." — Britt Vitalone, CFO

Two mechanisms are doing the work. The first is operating expense: the enterprise ratio of adjusted operating expense to adjusted gross profit improved 570 basis points, and this segment is where the physical automation program lives. The second is mix inside the segment, where the 10-Q notes that branded-to-generic conversion partially offset the revenue growth. Generic conversion lowers revenue dollars and raises the fee margin on the same script, so a quarter with heavy conversion prints a lighter top line and a better margin. That is a plausible partial explanation for a 1% revenue miss arriving alongside margin expansion.

Assessment: The direction is right and the driver is durable, but one quarter of 4 basis points is a data point rather than a trend, and the full-year guide of 5% to 9% operating profit growth implies second-half growth of roughly nothing to 7% against 11% in the first half. Management attributed that step-down to two comparability items rather than to margin. We accept the explanation and note that it makes the third and fourth quarters the real test.

Oncology & Multispecialty: The New Segment, and the Quarter's Only Accounting Question

Revenue grew 32% to $12,044M and adjusted operating profit grew 71% to $397M, at a 3.30% margin that is 77 basis points wider than a year ago. The reported growth rate is not the operating growth rate, and management said so unprompted in the prepared remarks. PRISM Vision and Core Ventures, both closed in the June quarter, contributed approximately 12 points of the segment's revenue growth and about half of its operating profit growth. A further $51M of nonrecurring net gains sits inside the reported number.

"Second quarter operating profit results also included nonrecurring net gains of $51 million from the sale of an equity investment in market decisions within the U.S. Oncology Network. Excluding the impact from the acquisitions of PRISM and Core Ventures and nonrecurring net gains, segment organic operating profit increased 13%, highlighting the strength and momentum of the core business." — Britt Vitalone, CFO

Thirteen percent organic is exactly the midpoint of the 13% to 16% long-term segment target introduced at Investor Day, so on the company's own framing this segment performed to plan and the headline is decoration. Excluding only the $51M, segment operating profit was $346M and the margin was 2.87%, still 34 basis points wider than a year ago and 18 basis points wider than the June quarter. The gains matter for the EPS line, not for the margin story.

Assessment: The disclosure here was better than the disclosure elsewhere on this call. Management sized the nonrecurring item, sized the acquisition contribution, gave the organic rate, and confirmed under direct questioning that the $51M covers both the equity gain and the market exits rather than only one of them. That is a segment being introduced with credibility. The open question is durability of the acquisition contribution once the anniversary arrives in the June 2026 quarter, at which point the segment has to deliver its 13% to 16% without a $2.5B deal in the base.

Prescription Technology Solutions: Revenue Down Sequentially, Margin Up, Guide Raised

Revenue grew 9% to $1,376M and adjusted operating profit grew 20% to $261M, at an 18.97% margin, 174 basis points wider than a year ago. Sequentially, revenue fell 4.0% and profit fell 3.0% while the margin rose 21 basis points. This is the segment we flagged in August as having the best economics and the least guidance follow-through, and this quarter it got the follow-through: the full-year operating profit range moved from 11% to 15% up to 13% to 17%, while the revenue range was left alone.

That is the mirror image of the first quarter, when a four-point revenue raise produced no profit raise. The explanation both times is mix between third-party logistics, which is high-revenue and low-margin, and technology and access services, which is the reverse.

"we're seeing more growth in our technology services components. And that is really all of the things that you mentioned. There are new products and programs that we're seeing growth in, and we're certainly seeing growth in some of our access programs like prior authorizations, particularly for GLP-1." — Britt Vitalone, CFO

The GLP-1 point deserves emphasis because it is the hedge inside the business. The same molecules that dilute the distribution margin percentage generate prior-authorization volume at nearly 19% margin. McKesson is on both sides of the trade.

Assessment: A profit guidance raise with the revenue range held is a higher-quality raise than the reverse, and it validates the mix explanation management gave in August. The caution is the second half, where the CFO explicitly guided to a step-up in investment spending. The full-year range implies second-half operating profit growth well below the 20% delivered in the first half, so investors should not extrapolate this quarter's rate.

Medical-Surgical Solutions: A Path Out, and a Weaker Illness Season on the Way

Revenue was flat at $2,947M and adjusted operating profit grew 2% to $249M, at an 8.45% margin. Sequentially the margin fell 58 basis points even as revenue rose 9.1%, which is the seasonal illness ramp arriving softer than the prior year. Management sized seasonal vaccines and testing as an approximate 4% revenue headwind, and the 10-Q shows sales to extended care customers down $12M against ambulatory care up $7M.

The company responded by cutting both segment ranges to the low end of 2% to 6% growth. That is the only guidance line in the entire package that moved down, and it moved down on the business McKesson intends to sell.

"Due to lower-than-anticipated illness season product volumes compared to the prior year, including vaccines and testing and lower volumes across ambulatory and extended care settings, we anticipate revenue and operating profit at the low end of 2% to 6% growth." — Britt Vitalone, CFO

Taking the low end literally, the full-year guide implies second-half segment operating profit roughly 5% below the prior year, against 11% growth in the first half. The cost optimization program is still working; the illness season is not cooperating.

Assessment: The operational read is unremarkable and seasonal. The strategic read is not. A business heading toward an initial public offering wants a clean earnings trajectory into the filing, and it just guided down on the one variable it cannot control. The separation is targeted for the second half of calendar 2027, so there is time to recover, but every quarter of illness-season weakness compresses the valuation McKesson can argue for when it markets the deal.

Corporate and Other

Adjusted corporate expenses were $151M against $170M, an 11% decline, and the entire movement is McKesson Ventures. The portfolio produced $3M of pre-tax gains this quarter against $15M of pre-tax losses a year ago. Excluding those, the CFO said corporate expenses were flat. The full-year range of $600M to $650M is unchanged, and with $289M spent in the first half the guide implies a meaningful step-up in the second, which is worth carrying in a model.

Other, which now holds Norway, produced $302M of revenue and $25M of adjusted operating profit against $14M a year ago. The $0.03 of held-for-sale accretion recognized this quarter runs through here.

Key Topics & Management Commentary

Overall Management Tone: Confident and specific, and materially more forthcoming on composition than on the August call. Where the first-quarter answers were directionally reassuring and quantitatively thin, this call led with sized disclosures before the questions arrived: the nonrecurring gains, the acquisition contribution, the organic rates by segment and in aggregate, and the discrete tax benefit were all volunteered in the prepared remarks. The one place management remained framework-level rather than quantitative was policy exposure, which was the same gap three months ago.

1. The Guidance Raise Is Operational, and Larger Than It Looks

McKesson raised full-year adjusted EPS guidance by $0.30 to $38.35 to $38.85. Unlike the August raise, which was entirely Norway held-for-sale accounting, this one is accompanied by three separate operating profit range increases and a reduction in the accounting benefit.

"For the full year, we now anticipate approximately $0.13 of adjusted earnings accretion due to held for sale accounting in fiscal 2026, which compares to our prior guidance of $0.20." — Britt Vitalone, CFO

The Norway benefit shrank by $0.07 while the range rose $0.30, so the operational component of this revision is roughly $0.37. Consolidated adjusted operating profit growth guidance moved from 10% to 14% up to 12% to 16%. North American Pharmaceutical moved from 3% to 7% up to 5% to 9%. Prescription Technology Solutions moved from 11% to 15% up to 13% to 17%. Interest expense guidance came down from $225M to $255M to $210M to $240M on debt portfolio management.

Assessment: This is the specific thing we said in August would move us. We wrote that an operational component to the next guidance revision would convert the back-half ramp from an assumption into an observation, and we got one, twice over, counting the $0.80 Investor Day raise in September. The thesis pillar on operating leverage is now confirmed rather than provisional. What it does not do is make the stock cheaper, because the market had already marked it.

2. The Resegmentation, and What It Was Built to Show

The old U.S. Pharmaceutical segment was 92% of revenue and buried the fastest-growing, highest-margin part of the distribution franchise inside the slowest. The new structure pulls specialty, provider solutions, and practice management into Oncology & Multispecialty, which now shows a 3.30% margin growing 32%, and leaves core distribution in North American Pharmaceutical at 0.98%.

"we implemented a new reporting structure beginning in the second quarter to enhance transparency and sharpen visibility into our growth platforms. This framework highlights the differentiated capabilities within our oncology and multispecialty and biopharma services platforms, verticals where McKesson is best positioned to deliver sustainable long-term growth." — Britt Vitalone, CFO

The recast history published on September 18 makes the point better than the commentary does. Across the five recast quarters, Oncology & Multispecialty revenue grew from $8,781M to $10,658M and its adjusted margin from 2.49% to 2.69%, while North American Pharmaceutical margin oscillated between 0.91% and 1.15% on volume that is nine times larger. Two businesses with completely different economics were previously reported as one.

Assessment: This is a genuine transparency improvement and it is also, unavoidably, a presentational one. Splitting a segment so that the growth engine reports separately from the volume engine is what a company does before it asks for a higher multiple on the sum. It happens to be justified here, because the underlying businesses really are different, but investors should be alert that the segment margin trends they will now track are three weeks old as a series, and that a five-quarter recast is a short history on which to build a model.

3. The Tax Line Gave $0.59, and Gives It Back in the Third Quarter

The adjusted effective tax rate was 17.5% against 21.0%, worth $0.59 per share on the company's own bridge. The mechanism was disclosed plainly.

"In the second quarter of fiscal 2026, we recognized net discrete tax benefits of $96 million, primarily related to the release of a valuation allowance compared to net discrete tax benefits of $44 million in the second quarter of fiscal 2025." — Britt Vitalone, CFO

The full-year range moved up at the bottom, from 17% to 19% to 18% to 19%, and management guided the third quarter to 23% to 25% with a lower fourth quarter. That is a large, dated reversal. The first half ran at 19.3% on adjusted pre-tax income, which is above the top of the full-year band, so for the year to land inside 18% to 19% after a 23% to 25% third quarter, the fourth quarter has to run well below the full-year range.

Assessment: Nothing here is improper and the discretes are disclosed, but a reader modelling forward should understand that the tax line was a $0.59 tailwind this quarter and is guided to be a headwind next. Consensus for the third quarter will need to reflect a rate roughly six points higher sequentially. A quarter that optically decelerates hard from 39% growth is coming, and at 22.2x the market is paying in advance for a year whose remaining shape is the least flattering part of it.

4. Operating Leverage: 570 Basis Points, and a Second Data Point

The single most durable thing in this quarter is the expense line. Adjusted operating expenses fell 1% in absolute dollars while revenue grew 10% and two acquisitions sat in the base.

"Operating expenses as a percentage of gross profit declined 570 basis points, delivering significant operating leverage as we accelerate and modernize our operations." — Britt Vitalone, CFO

The claim checks against the reported lines: $1,964M of adjusted operating expenses on $3,534M of adjusted gross profit is 55.6%, against $1,989M on $3,246M, or 61.3%. Last quarter the same calculation produced 450 basis points. Management attributes it to automation, to the divestiture of the Canadian retail businesses, and to cost optimization in Medical-Surgical, and the CEO framed it as the harvest of a long capital cycle.

"this is really, in many ways, some of the manifestation of investments we made in years prior, whether to do physical automation, use digital technologies to automate processes. And those -- these are big projects often. They can take years." — Britt Vitalone, CFO

Assessment: In August we called a multi-year operating-leverage framework the single most valuable disclosure the company could make, and the September Investor Day answered indirectly by raising the long-term adjusted EPS growth target to 13% to 16% from 12% to 14%. That is the framework, expressed as an outcome rather than as a runway. It is less than we asked for and more than we had. Two consecutive quarters of accelerating improvement in the same ratio is a real signal in a business that earns 1.6 cents on the revenue dollar.

5. Medical-Surgical Separation: Structure, Sequence, and a Date

The August report said the separation was an intent and nothing else three months after announcement. It now has a form and a target.

"we anticipate exiting the business by way of an initial public offering. Following a customary lockup period, McKesson intends to exit its remaining interest through a spin-off or a split-off transaction or potentially a combination of both. We currently anticipate that this separation could be completed by the second half of calendar 2027, subject to market conditions and customary regulatory approvals." — Britt Vitalone, CFO

The fiscal 2026 outlook assumes 100% ownership throughout, so nothing in the current guide reflects the separation. An initial public offering ahead of a spin or split is a more deliberate path than a straight spin: it establishes a public price before McKesson distributes the residual, which protects the exchange ratio in a split-off and gives the standalone company an independent capital structure. It is also slower, and it exposes the timeline to equity market conditions in a way a straight spin does not.

Assessment: Two of the three things we asked for at the September event arrived. The structure and the timeline are disclosed. The stranded-cost estimate is not, and it does not appear in the release, the deck, or the 10-Q. Until it does, the sum-of-the-parts case runs on an unpriced liability, and separations of this kind reliably disclose that number late and larger than the first framing. The target date of late calendar 2027 also means this is not a near-term catalyst, and any investor underwriting it today is underwriting roughly two years of execution.

6. The Investor Day: The Long-Term Algorithm Went Up

On September 23, mid-quarter, McKesson raised its long-term adjusted EPS growth target to 13% to 16% from 12% to 14%, introduced segment-level long-term targets for the first time, and raised and narrowed fiscal 2026 guidance to $38.05 to $38.55 from $37.10 to $37.90. The segment targets are 5% to 8% for North American Pharmaceutical, 13% to 16% for Oncology & Multispecialty, and 10% to 13% for Prescription Technology Solutions. There is no published long-term target for Medical-Surgical, which is consistent with the intent to separate it.

"At our Investor Day, we raised our earnings per diluted share outlook by $0.80 to a range of $38.05 to $38.55, which was a testament to the clarity of our strategy, strength of our portfolio and disciplined execution." — Britt Vitalone, CFO

Assessment: The introduction of segment-level long-term targets is the more useful of the two changes, because it lets investors check any given quarter against a stated algorithm rather than against a blended company number. This quarter, Oncology & Multispecialty organic operating profit grew 13%, the floor of its target, and North American Pharmaceutical grew 13% against a 5% to 8% target, well above. The raise in the enterprise target from 12% to 14% up to 13% to 16% is the reason the valuation argument has become harder rather than easier: the growth rate went up, but the multiple went up faster.

7. The Acquisitions Are Tracking, and the Anniversary Is Coming

PRISM Vision and Core Ventures, the services organization behind Florida Cancer Specialists, closed in the June quarter for roughly $3.4B of cash. Management guided at the start of the year to $0.40 to $0.60 of accretion from Core Ventures and $0.20 to $0.30 from PRISM, and now says both are tracking, with PRISM slightly ahead. Combined they are guided to contribute approximately 30 to 34 percentage points of the Oncology & Multispecialty segment's fiscal 2026 operating profit growth.

"they're both relatively in line with the guidance that we provided. I would say that PRISM is probably slightly ahead. And certainly, our ability to continue to add providers to that platform when we add to that." — Britt Vitalone, CFO

The platform is compounding rather than sitting still. PRISM added Spokane Eye Clinic on October 31, taking the retina and ophthalmology platform outside the mid-Atlantic for the first time, and the CEO described the addition of 27 eye care specialists across four clinic locations.

Assessment: The commitment we set in August was that PRISM and Core Ventures deliver the promised profit contribution, and the evidence so far supports it. What investors should carry forward is the arithmetic of the anniversary. When these deals lap in the June 2026 quarter, roughly 30 points of segment profit growth and 6 points of consolidated growth come out of the comparison, and Oncology & Multispecialty has to produce its 13% to 16% target unaided. The CFO's reminder that Core Ventures was debt-funded and carries noncontrolling interests below the line is also the right caution: the operating profit contribution overstates the EPS contribution.

8. Cash Generation Snapped Back, and the Full-Year Guide Implies It Slows

Free cash flow was $2,224M in the quarter after $196M of capital expenditure, against negative $1,107M in the June quarter, a swing of $3.3B. First-half free cash flow of $1,117M compares with $335M a year ago. The cash balance rebuilt from $2,418M to $4,004M despite $907M of capital returns, comprising $818M of buybacks and $89M of dividends.

The full-year guide is unchanged at $4.4B to $4.8B against $5.2B of actual free cash flow in fiscal 2025. With $1,117M delivered in the first half, the guide implies $3.3B to $3.7B in the second half against roughly $4.9B in the prior-year second half. Nobody asked about that, and management did not volunteer it.

Assessment: A working-capital-negative distributor generates cash in a lumpy pattern, and a guide that was set before the first half came in this strong is more likely to be conservative than to be a warning. But it is the one line in the outlook that implies a materially worse second half than the prior year, and it sits alongside a $2.5B buyback commitment of which only $1.4B has been executed. The absence of any question on it is a gap in the Q&A rather than a gap in the business.

9. Policy: The Cash-Pay Channel, and Still No Sizing

The policy questions rotated from most-favored-nation letters in August to the direct-to-patient cash-pay channel in November, and the answer had the same shape: reasoned, qualitative, unsized.

"the view that we would hold right now is that the population that's eligible and can afford even the discounted prices really remains pretty small based on assessment that we've done to this point in time. And therefore, we don't see a big impact on the prior authorization business." — Brian Tyler, CEO

The CEO's substantive point is that direct-to-patient pharmacy has existed for over a decade and that McKesson already supplies automation, patient interface, and last-mile tooling into those channels, so a shift in dispensing route is not obviously a loss of position. That is a fair argument. It is also the third consecutive quarter in which a live policy vector affecting the majority of revenue has been addressed without a range.

Assessment: The 10-Q filed the following morning narrows rather than widens the disclosure. Its entire "Trends and Uncertainties" section is a single paragraph headed "Government Policies" that says regulatory outcomes "are difficult to predict." Tariffs, most-favored-nation pricing, and the cash-pay channel appear nowhere in the filing. Distributors are structurally better insulated from drug-price policy than manufacturers, because they earn fees rather than spreads, and we continue to think the exposure is second-order. But an unquantified overhang stays a multiple constraint until someone quantifies it, and at 22.2x that constraint is more binding than it was at 17.7x.

10. The Supply Chain Security Implementation, and Why It Is Not a Moat

McKesson went live in August with serialized transaction data exchange under the Drug Supply Chain Security Act, a multi-year technology program across the U.S. Pharmaceutical business. Asked whether the requirement raises barriers against smaller distributors, the CEO declined the invitation.

"Given the structure of our markets, I'm not thinking it's going to be a material driver of anything. Our key focus was to make sure we serve both our upstream manufacturer partners well, our downstream partners well and that we could transmit the business and keep the supply chain operating reliably, safely and in compliance with laws." — Brian Tyler, CEO

Assessment: Refusing an offered competitive-advantage narrative is a small thing that says something real about how this management team communicates. The three-player structure of U.S. pharmaceutical distribution was already about as concentrated as regulation permits, so a compliance program that every incumbent completed does not change relative position. It is a cost of doing business, cleanly executed, and management said so.

11. The Balance Sheet After the Acquisition Quarter

Total debt was $7,758M at September 30 against $5,654M at March 31, comprising $1,747M of current maturities and $6,011M of long-term debt, and cash was $4,004M against $5,691M. Goodwill rose to $11,283M from $10,022M and intangible assets to $4,220M from $1,464M, both consequences of the June-quarter acquisitions. A new $777M redeemable noncontrolling interest line appeared, reflecting the minority stakes retained in the acquired practice-management platforms. Long-term litigation liabilities fell to $5,103M from $5,601M, and the company paid $657M against litigation liabilities in the first half.

Assessment: The company entered the fiscal year approximately net-cash-neutral and is now carrying roughly $3.8B of net debt after $3.4B of acquisitions, which is comfortable against a business guiding to $4.4B to $4.8B of annual free cash flow. Interest expense guidance came down despite the higher balance, which is a real result of portfolio management rather than a rounding item. The redeemable noncontrolling interest is the line to watch: it is the mechanism by which the minority holders in the acquired practices can eventually put their stakes back, and it is not discussed anywhere in the earnings materials.

Guidance & Outlook

Consolidated Fiscal 2026 Guidance

Segment Fiscal 2026 Guidance

The Guidance Walk Across Fiscal 2026 to Date

Implied second-half ramp: first-half adjusted EPS of $18.12 against a full-year range of $38.35 to $38.85 leaves $20.23 to $20.73 for the remaining two quarters. The prior-year second half produced $18.10, being the $33.05 full-year result less $14.95 of first-half earnings. The guide therefore requires 11.8% to 14.5% growth over the second half, after 21.2% in the first. That is a deceleration, and management attributed the segment-level version of it to two comparability items in North American Pharmaceutical rather than to any change in run rate.

The back-half load has eased, not tightened. This is the more important framing and it reverses the concern we raised in August. First-half earnings represent 46.9% of the new guidance midpoint. A year ago the first half represented 45.2% of the eventual full-year result. The year is now less back-half weighted than fiscal 2025 was, which is the opposite of where the first quarter left it.

Street at: consensus for the quarter sat at $9.04 of adjusted EPS on $104.15B of revenue. The new full-year midpoint of $38.60 is $0.30 above the range management set at Investor Day six weeks earlier, and the Street had broadly aligned to that range in the interval.

Guidance style: McKesson has now raised the fiscal 2026 range at four consecutive disclosure points, cumulatively $1.45 at the midpoint from the May starting range. The pattern is a company that sets a range it intends to walk upward. Two of the four raises were operational, one was accounting, and the largest came at a scheduled investor event rather than at an earnings print. Reading that forward, the third-quarter print in early February is more likely to be a modest raise than a large one, because the tax reversal lands in the same quarter.

Analyst Q&A Highlights

Whether the Highest-Margin Segment Can Hold Its Margin Through a Spending Ramp

The first question of the call asked what is actually driving margin expansion in Prescription Technology Solutions, and whether the investment step-up flagged at Investor Day changes the second-half shape. The answer did both jobs: it named the mix shift toward technology services and access programs, and it confirmed without hedging that spending rises in the back half. That is a more useful answer than the segment received in August, when a four-point revenue guidance raise came with no profit follow-through and no explanation of the shape.

Q: "When I look at the revenue growth versus the operating profit expansion, especially in North America Pharmaceutical as well as Prescription Technology Solutions, I heard what you said, Britt, especially in your last comments around it all being organic growth when we think about Prescription Technology Solutions. But -- is it new products you're bringing to the market? Is it enhanced programs that are driving that margin?"
— Lisa Gill, JPMorgan

A: "As it relates to the investments, yes, you did hear that right, and we do anticipate a higher level of investments in the second half of the year. So you think about the cadence for the year. Certainly, we had very strong operating profit growth in that segment in the first half of the year. We expect that to continue to be strong in the second half of the year, and that's going to be against an increased level of investment spending that we have included in our guidance for the balance of the year."
— Britt Vitalone, CFO

Assessment: The exchange sets the right expectation before the model gets ahead of itself. A 20% first-half growth rate against a 13% to 17% full-year range was always going to require a slower second half, and management said so at the first opportunity rather than letting the question sit. The raise is credible precisely because it came with the offset attached.

Whether the Segment Beat Was Already Inside the Six-Week-Old Guidance

The sharpest structural question of the call asked why a segment that grew operating profit 71% did not produce a segment guidance raise, and whether the upside had already been contemplated at Investor Day. The response is a small but revealing admission: most of the nonrecurring items were already in the September guide, and only the timing of one of them changed.

Q: "Maybe just as I think about oncology and multispecialty, strong results there, but you're maintaining the guidance. Just curious, was the beat in the quarter essentially already contemplated in your guide when you did Investor Day and highlighted expectations for that business?"
— Brian Tanquilut, Jefferies

A: "We did call out some nonrecurring gains. Most of -- there were 3 items really that made up that, that all happened in this quarter. The majority of those were known and included in the guidance at Investor Day. There was a third item here that the cadence of that was more back half weighted in our guidance than we had at Investor Day."
— Britt Vitalone, CFO

Assessment: This is the most important answer on the call for anyone modelling the second half. It confirms that the segment's apparent upside is timing rather than magnitude, which is exactly why the segment guidance did not move while two others did. It also means the fourth quarter loses a gain the original guide had placed there. Investors treating 71% growth as a new run rate are reading the wrong number, and management was candid enough to say so when asked directly.

Pinning Down What the Nonrecurring Gain Actually Contained

A follow-up refused to accept the composite framing and asked whether the equity gain sat inside the $51M or on top of it. The answer was one sentence and fully responsive, which is worth noting given how often this kind of question produces a paragraph that resolves nothing.

Q: "But just in terms of the actual like item that you recorded in the quarter, I mean, it sounds like the gain was something separate and related to an equity investment. Just trying to understand like what the actual economic impact in the quarter is. And is that included in the $51 million that you sized? Or is that something that's incremental?"
— Stephen Baxter, Wells Fargo

A: "Just to clarify, the gains in the market decisions together represent the $51 million."
— Britt Vitalone, CFO

Assessment: The $51M is the ceiling, not a component, which caps the adjustment investors need to make and closes off the worst reading. Combined with the disclosure that two markets were exited, the picture is a portfolio-pruning quarter that happened to coincide with an investment realization. Management's framing that three such items landing together is unusual is credible on its face, and the right posture is to exclude all of it from the run rate rather than to argue about which piece was operational.

The Tax Rate Cadence Through the Back Half

A recurring line of questioning pressed on why the full-year rate band tightened upward when the reported quarter came in so far below it. The answer supplied specific quarterly guidance, which is not something this company routinely does, and effectively pre-announced the shape of the third quarter.

Q: "Full year, you're still guiding 18% to 19%, actually brought it up towards the higher end. How should we think about tax rate in the back half of the year?"
— Charles Rhyee, TD Cowen

A: "we are anticipating that the second half will have a slightly higher rate than we had at Investor Day. That's what's really driving the guidance from 17% to 19% to 18% to 19%. That's really just a modest change in our outlook there. But as I provided here, we gave you specific tax rate guidance for the third quarter. We anticipate that the third quarter will come in right around 23% to 25%. And we would anticipate that the timing of some discretes and mix of income will drive a lower rate in our fourth quarter."
— Britt Vitalone, CFO

Assessment: Giving a specific quarterly tax range is a courtesy and also a warning. A rate moving from 17.5% to the mid-twenties sequentially is a several-point headwind to third-quarter growth on its own, and the full-year band only closes if the fourth quarter runs well below it. The stock is being asked to hold a 22x multiple through the one quarter of this fiscal year in which the reported growth rate will look worst.

Why the Largest Segment's Growth Halves in the Second Half

The most numerically precise challenge of the call worked backwards from the segment guide to an implied second-half growth rate of roughly 3.5%, against north of 11% delivered in the first half, and asked what else was in it besides investment. The answer named two specific comparability items and nothing else, which is the shape of answer that can be checked.

Q: "If I look at the Pharma segment growth in the first half of the year, the actual is north of 11% and would imply the second half is less than 4%, 3.5% roughly. I know there's some investments in spend. Is there anything else to call out incrementally from what you've achieved in the first half of the year versus what would happen in the second half of the year just in the U.S. Pharma segment?"
— Kevin Caliendo, UBS

A: "I would point to 2 things. As you may recall, last year, we onboarded a new strategic customer into this segment that started in the second quarter of fiscal 2025. So first half of this year would have incremental quarter of operations from that particular customer. And last year, as I mentioned in my remarks, we exited our Canada-based Rexall and Well.ca businesses. And as a result of that, we had some held for sale accounting accretion in last year's numbers. Those 2 things are really the key drivers for the first half versus second half."
— Britt Vitalone, CFO

Assessment: Both items are verifiable from prior disclosure and both are genuine comparability effects rather than deterioration, so the implied slowdown is arithmetic rather than fundamental. The residual worry is that a segment guided to 5% to 9% for the year, delivering 13% in the quarter just reported, is being guided to roughly flat in the back half, and management chose not to raise the range further despite that gap. Either the comparability effects are larger than they sound or there is conservatism embedded, and the third quarter will separate the two.

Three Consecutive Quarters of Falling Operating Expense

A question tried to establish whether declining absolute operating expense alongside accelerating gross profit is a repeatable dynamic or a divestiture artifact. The answer credited both, and then extended into the technology argument that has become the company's principal operating narrative.

Q: "This was the third straight quarter where SG&A was down year-over-year and gross profit is actually accelerating. I know that you don't give quarterly guidance around those metrics or those metrics in general. But it seems like a pretty unique dynamic. You talked a little bit about first half, second half. How should we think about that trend in the first half of the year and the trajectory of gross profit and SG&A into the back half of fiscal '26?"
— Allen Lutz, Bank of America

A: "I talked about how we lead with a technology first and focusing on AI and modernizing our businesses. And that's driving a significant amount of operating expense efficiency, which certainly is good for all stakeholders that McKesson deals with. So I think we're very pleased with the quality of the operations and the quality of relationships we have that are driving a more favorable gross margin mix."
— Britt Vitalone, CFO

Assessment: The Canadian divestiture is a real component and management named it first, which is the honest ordering. What remains after that adjustment is still the most important operating fact in the business, and the ratio evidence supports it. The answer again stopped short of a forward rate, which remains the disclosure gap we identified in August, though the raised long-term earnings algorithm now supplies an implied one.

How the Acquisitions Are Tracking Against Their Original Accretion Targets

The final question of the call held management to the specific per-share accretion figures given when the deals were announced, rather than accepting the newly disclosed operating profit contribution as a substitute. The answer accepted the challenge and added the below-the-line caveat that most companies would have left out.

Q: "I think at the beginning of this fiscal year, you guys provided some color around the accretion from the 2 acquisitions. I think it was $0.40 to $0.60 from Florida Cancer Specialist and $0.20 to $0.30 from PRISM. And I guess today you're disclosing the 2 acquisitions combined are going to add, I think it was 30 to 34 percentage points to operating profit growth. But just curious, are you able to provide more color on just each individual acquisition and how it's performing relative to those original EPS accretion guidance metrics, the way things stand right now?"
— Steven Valiquette, Mizuho Securities

A: "What we've provided you with that 30% to 34% is the adjusted operating profit impact. I would remind you that in the acquisition of Core Ventures, we did raise debt against that. And we also had some noncontrolling interest that goes below the line. That being said, as Brian and I both mentioned, we're really pleased with the progress of both acquisitions. And I would say that they're both relatively in line with the guidance that we provided."
— Britt Vitalone, CFO

Assessment: The reminder that segment operating profit contribution is gross of interest and minority interest is exactly the right caveat and it was volunteered, not extracted. It is also the reason the 30 to 34 point figure should not be converted to EPS by any reader. On the substance, "relatively in line" with one deal slightly ahead is a pass on a commitment we set at initiation, and the platform continues to add providers, which is the mechanism by which the accretion compounds beyond the original guide.

What They're NOT Saying

1. Any stranded-cost estimate for the Medical-Surgical separation. The structure and the target date are now disclosed, but the number that determines whether the separation creates value is not. It appears nowhere in the press release, the earnings presentation, or the 10-Q filed the following morning, where the segment discussion still reads only that the company "announced its intention to separate this segment into an independent company." The initial public offering structure that management described on the call does not appear in the filing at all.
2. Any GLP-1 disclosure outside the call. This is the second consecutive quarter in which $13B of revenue, 12.8% of the consolidated top line, is quantified verbally and appears in no filed document. The 10-Q does not contain the term. Without a filed disclosure, no investor can build a GLP-1 series, check the growth rate, or separate its economics from the rest of North American Pharmaceutical.
3. Any sizing of policy exposure, in a section that got shorter. The 10-Q's entire "Trends and Uncertainties" discussion is now one paragraph headed "Government Policies," concluding that outcomes "are difficult to predict." Tariffs, most-favored-nation pricing, and the cash-pay channel appear nowhere in the filing. A quarter ago the same section at least discussed opioid litigation and Rite Aid specifically.
4. Why full-year free cash flow guidance implies a much weaker second half. First-half free cash flow of $1,117M against an unchanged $4.4B to $4.8B full-year range implies $3.3B to $3.7B in the second half, against roughly $4.9B in the prior-year second half. No question was asked and no explanation was offered.
5. What happens to Oncology & Multispecialty growth when the acquisitions lap. Management disclosed that PRISM and Core Ventures contribute 30 to 34 points of the segment's fiscal 2026 operating profit growth and about half of it this quarter, but gave no framing for the June 2026 quarter, when that contribution leaves the comparison and the segment must produce its 13% to 16% target from the organic base alone.
6. The redeemable noncontrolling interest. A $777M line appeared on the balance sheet that did not exist at March 31, representing the minority positions retained in the acquired practice-management platforms. It is not mentioned in the release, the deck, or the prepared remarks, and the terms on which those interests can be redeemed are a future call on cash that nobody discussed.
7. The Norway financial impact, five quarters into the process. Guidance still embeds accretion from held-for-sale treatment, now $0.13 rather than $0.20, while the 10-Q continues to state that the company "is currently evaluating the financial impact of the transaction" and that the sale is anticipated to close after fiscal 2026. Net assets held for sale are $112M. No purchase price or gain estimate has been disclosed.

Market Reaction

• Pre-print setup: MCK closed at $844.26 on November 5, up 48.1% year to date against a 15.6% gain for the S&P 500, up 60.7% over the trailing twelve months and up 13.9% over the trailing 30 days. The 52-week closing range was $525.28 to $844.26, so the stock entered the print at its highest close of the trailing year, having set a 52-week intraday high of $863.32 that same session.
• Print timing: results were released after the close on November 5, with the conference call at 4:30 p.m. ET, so the reaction traded in the following session.
• After-hours move: roughly flat, up about 0.3% on modest volume. The initial print reaction contained essentially no information.
• Reaction session: MCK opened at $832.35 on November 6, a 1.4% gap lower, then traded a $793.31 to $860.00 range and closed at $858.61, up 1.7% or $14.35 on the day and within $1.39 of the session high. The intraday range was $66.69, or 7.9% of the pre-print close.
• Volume: 1.1 million shares against a 0.7 million 30-day average, 1.6 times normal. Elevated, but nothing like the 3.2 times that accompanied the August selloff.
• Relative: the S&P 500 fell 1.1% on the session and traded below its 50-day moving average intraday for the first time since April. Cencora rose 1.8%, Cardinal Health rose 0.6%, and the health-care sector ETF rose 0.2%. MCK outperformed the index by 2.8 points and led both direct peers.
• Follow-through: the stock closed at $851.99 on November 7, down 0.8%, giving back less than half of the reaction-day gain.

The shape of the session matters more than the close. A stock that had gained 48% year to date, sitting at its 52-week closing high, gapped down and then traded 6% below its pre-print close during the morning before reversing the entire move and finishing near the day's high. That is a position being tested and held. The early weakness has two plausible sources and probably both: a 1% revenue miss is the kind of headline that trades first and gets analyzed second, and the broad market was down more than 1% with the index breaking its 50-day average.

What brought the stock back was almost certainly the composition of the guidance raise rather than the print. The quarter itself is ambiguous once the tax rate and the $51M of gains are stripped out. The guide is not: three operating profit ranges raised, the accounting benefit cut, and the only downward revision confined to the segment on its way out the door. An investor reading the release in order encounters the revenue miss first and the operational raise several pages later, which is a reasonable explanation for a session that traded down 6% and closed up 1.7%.

The relative performance is the cleanest signal available. Closing 2.8 points ahead of the index on a broad risk-off day, and ahead of both distributor peers, in a group that was already bid after Cencora's own results the previous session, says the market read this as a good quarter for the sector and a slightly better one for McKesson. It also means the stock now carries a multiple that leaves less room for the next disappointment.

Street Perspective

Debate: Has the GLP-1 Margin Problem Actually Been Solved?

Bull view: the bull case on the Street is that this quarter settles it. North American Pharmaceutical margin expanded 4 basis points year over year while GLP-1 revenue grew 24% to $13.2B and rose as a share of the segment. If the segment can widen its margin while absorbing more of the dilutive product, then the dilution was never the binding constraint and operating leverage was always the larger force.

Bear view: the bear camp contends that 4 basis points is inside the noise of a business that earns one cent on the revenue dollar, and that the improvement is explained by branded-to-generic conversion and the absence of the divested Canadian retail businesses rather than by anything structural. One quarter after a 12 basis point contraction is a reversal, not a trend, and the company still publishes no disclosure that would let anyone separate GLP-1 economics from the rest of the segment.

Our take: the bulls are closer to right and are claiming too much. The mechanism is real and the direction changed, which is why we are moving this bear point from confirmed to challenged rather than leaving it in place. But the bear point about disclosure is unchanged and unanswerable from the outside: a company that quantifies a $13.2B revenue line only on a webcast is asking investors to take the margin bridge on trust. We want two more quarters of expansion before we call this resolved.

Debate: Is the Second-Half Deceleration Conservatism or Reality?

Bull view: the bull framing is that management has raised the range four times this fiscal year, most recently while absorbing a $0.07 reduction in accounting accretion, and has a documented pattern of guiding to a number it then walks up. The second-half step-down in the largest segment is fully explained by two named comparability items. The company would not be raising three operating profit ranges if it saw strain.

Bear view: the skeptics point out that the second-half guide requires 11.8% to 14.5% adjusted EPS growth after 21.2% in the first half, that the third quarter carries a tax rate six points higher sequentially, that Medical-Surgical was guided down, that Prescription Technology Solutions faces a disclosed investment step-up, and that the fourth quarter loses a nonrecurring gain the original guide had placed there. That is five separate headwinds landing in two quarters.

Our take: both are right about different things, and the resolution is that the deceleration is real and mostly benign. Every item the bears list is either a comparability effect, a disclosed timing shift, or a tax reversal that annualizes away. What the bulls understate is the optics: the third quarter is going to print a growth rate that looks nothing like this one, and a stock at 22.2x is not positioned for an optically weak quarter even when the arithmetic is innocent.

Debate: Does the Portfolio Reshaping Justify the Re-Rating?

Bull view: the bull case is that the Investor Day changed the company's identity in the market's eyes. The long-term earnings algorithm went to 13% to 16% from 12% to 14%, the growth engine now reports as its own segment with a 3.30% margin, Medical-Surgical has a defined exit path, and the European exit is finished. A business compounding earnings in the mid-teens with negative working capital, a shrinking share count, and two value-releasing events ahead is worth more than a distribution multiple.

Bear view: the bear camp contends the re-rating has run ahead of the delivery. The multiple went from 17.7x the guidance midpoint in August to 22.2x today while the guidance midpoint rose 3%, which means almost the entire move was multiple rather than earnings. The Medical-Surgical exit is nearly two years away, carries an undisclosed stranded cost, and starts with an initial public offering whose timing depends on equity market conditions. Segment reporting changes do not create value on their own.

Our take: the bulls have won the argument and the bears have won the price. The strategic direction is right, the operational evidence arrived, and the raised algorithm is defensible. But paying 22.2x for a business whose separation catalyst lands in late calendar 2027, with no stranded-cost figure disclosed, is underwriting execution over a two-year horizon at a valuation that assumes it goes well. We would rather own this at 19x than at 22x, and there is no rule that says we get to choose.

Model Update & Valuation Framework

Valuation: at the November 6 close of $858.61, McKesson trades at 22.2 times the fiscal 2026 guidance midpoint of $38.60. At the pre-print close of $844.26 against the prior midpoint of $38.30, it traded at 22.0 times, so this print did essentially nothing to the multiple. The re-rating happened in September: on August 7 the stock closed at 17.7 times the then-current midpoint of $37.50. Roughly four and a half turns of multiple have been added in three months against a 3% increase in the guidance midpoint.

Rolling forward, management's raised long-term target of 13% to 16% adjusted EPS growth implies fiscal 2027 earnings of roughly $43.60 to $44.80, which puts the stock at 19.2 to 19.7 times a year that begins in five months. That is a defensible multiple for a business with an oligopoly structure, negative working capital, a shrinking share count, and a mid-teens algorithm. It is not a cheap one, and it is no longer the "multiple below the growth rate" that anchored our initiation.

What would move us to Outperform: a third-quarter print that delivers on the raised operating profit ranges without tax or nonrecurring assistance, a stranded-cost figure for the Medical-Surgical separation that leaves the sum-of-the-parts case intact, a filed GLP-1 disclosure that lets the margin bridge be checked from outside, or a de-rating toward 19 times fiscal 2026 that does not come with a downgrade to the guide.

What would move us to Underperform: a third quarter in which North American Pharmaceutical margin resumes contracting, evidence that the Oncology & Multispecialty organic rate is below the 13% floor of its own long-term target once acquisition contribution is removed, a Medical-Surgical separation delayed beyond calendar 2027 or accompanied by dis-synergies that exceed the value released, or a fiscal 2027 guide that lands below the 13% to 16% algorithm management just raised.

Thesis Scorecard Post-Earnings

Overall: the thesis strengthened materially. Three of four bull pillars are confirmed by hard numbers in this quarter's own disclosures, against two of four in August. Two of three bear points moved from confirmed to challenged. The one bear point that got worse did so on disclosure quality rather than on business impact. Every condition we named in August as a trigger for an upgrade was met: the largest segment's profit inflected, the guidance revision was operational, and the separation acquired a structure and a date.

Action: hold. The rating is unchanged and the reason is entirely price. The business case has moved from provisional to demonstrated, and had this quarter printed with the stock at $700 we would be upgrading. It printed with the stock at its 52-week high, at 22.2 times the guidance midpoint against 17.7 times when we initiated, having absorbed a four-and-a-half-turn re-rating in three months on a 3% increase in the guidance midpoint. The next two quarters carry a tax reversal, a disclosed investment step-up, a guided-down Medical-Surgical, and the loss of a nonrecurring gain, which is an unattractive setup for a premium multiple even when every item is benign. Conviction rises from 5 to 6; the rating waits for a better entry or for a third quarter that delivers the raised ranges without assistance.